Banca de DEFESA: SÁVIO BRUNO ARAÚJO DINIZ

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : SÁVIO BRUNO ARAÚJO DINIZ
DATE: 24/02/2026
TIME: 08:30
LOCAL: Link será definido posteriormente
TITLE:

Drug Interactions in Hemodialysis Patients: A Multicenter Cross-Sectional Study

KEY WORDS:

Drug Interactions, Hemodialysis, Pharmaceutical Care

PAGES: 82
BIG AREA: Ciências da Saúde
AREA: Farmácia
SUBÁREA: Farmácia clínica, assistência e atenção farmacêuticas
SUMMARY:

Introduction: Chronic kidney disease (CKD) is a prevalent condition that, in advanced stages, necessitates renal replacement therapy, most commonly hemodialysis (HD). Patients undergoing outpatient HD utilize complex pharmacotherapy due to the development and progression of comorbidities, thus facilitating the occurrence of pharmacotherapy-related problems, one of the main ones being drug interactions (DIs). Objective: To evaluate the prevalence, severity, and factors associated with potential DIs in CKD patients undergoing renal replacement therapy via HD. Methodology: This was a cross-sectional, prospective, and multicenter study conducted with data from patients with chronic kidney disease (CKD) undergoing outpatient hemodialysis (HD) at 13 health centers located in 3 capital cities of Northeast Brazil, between August 2019 and July 2021. Data were collected through interviews, interactions were analyzed using the UpToDate Lexidrug® platform, and statistics were performed using Stata® version 15. Results: 1,114 patients participated in the study, the majority of whom were hypertensive (47.5%), with a mean age of 48.2 years (± 13.9). Among the included patients, 496 (44.5%) presented a risk of at least one potential drug interaction. According to the severity classification, 792 (81.82%) were risk category C and 25 (2.58%) were risk category X (significant severity). We found 297 interaction pairs, the most frequent being between calcitriol and sevelamer (144; 14.87%). We found a significant correlation between drug interactions and polypharmacy (OR = 7.97; p < 0.001), age (OR = 1.01; p = 0.025), diabetes (OR = 1.55; p = 0.012), and lupus (OR = 2.72 p = 0.008). Conclusion: The study suggests a high prevalence of potential drug interactions (DIs) in hemodialysis (HD) patients, associated with polypharmacy, advancing age, and the presence of diabetes and lupus. The findings reinforce the importance of monitoring potential drug interactions, highlighting that periodic medication review is fundamental in patients with chronic kidney disease (CKD) undergoing outpatient HD. It is hoped that the results can assist healthcare professionals in identifying DIs and ensuring the safety of pharmacotherapy in this population.

COMMITTEE MEMBERS:
Externo à Instituição - ARTUR QUINTILIANO BEZERRA DA SILVA
Presidente - 3315645 - FRANCISCA SUELI MONTE MOREIRA
Interna - 347795 - IVONETE BATISTA DE ARAUJO